Cargando…

Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial

BACKGROUND: Adrenomedullin (AM), an endogenous vasodilative peptide, has immunomodulative effects and acts as an accelerator of mucosal regeneration in the digestive tract. AM has shown beneficial effects in rodent models of inflammatory bowel disease and patients with ulcerative colitis. The presen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kita, Toshihiro, Kaji, Yoshikazu, Kitamura, Kazuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955635/ https://www.ncbi.nlm.nih.gov/pubmed/32021087 http://dx.doi.org/10.2147/DDDT.S225220

Ejemplares similares

Adrenomedullin for biologic‐resistant Crohn's disease: A randomized, double‐blind, placebo‐controlled phase 2a clinical trial
por: Kita, Toshihiro, et al.
Publicado: (2022)

Adrenomedullin Therapy in Moderate to Severe COVID-19
por: Kita, Toshihiro, et al.
Publicado: (2022)

Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases
por: Kita, Toshihiro, et al.
Publicado: (2022)

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects
por: Liu, Chao, et al.
Publicado: (2019)

Adrenomedullin: A Novel Therapeutic for the Treatment of Inflammatory Bowel Disease
por: Ashizuka, Shinya, et al.
Publicado: (2021)

Adrenomedullin Therapy in Patients with Refractory Ulcerative Colitis: A Case Series
por: Ashizuka, Shinya, et al.
Publicado: (2015)

First‐in‐human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males
por: Moschetti, Viktoria, et al.
Publicado: (2016)

Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial
por: Kita, Toshihiro, et al.
Publicado: (2020)

Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
por: Tummala, Raj, et al.
Publicado: (2018)

Safety and pharmacokinetics of EP-104IAR (sustained-release fluticasone propionate) in knee osteoarthritis: A randomized, double-blind, placebo-controlled phase 1 trial
por: Malone, Amanda, et al.
Publicado: (2021)

Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab
por: Ashizuka, Shinya, et al.
Publicado: (2019)

Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects
por: Boettcher, Michael, et al.
Publicado: (2020)

Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants
por: Maden, Charlotte H., et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
por: Härtter, Sebastian, et al.
Publicado: (2012)

Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study
por: Mendzelevski, Boaz, et al.
Publicado: (2012)

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
por: Jenkins, H, et al.
Publicado: (2015)

Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects
por: Shin, Donghoon, et al.
Publicado: (2020)

Ocular side effects of Levitra(®) (vardenafil) – results of a double-blind crossover study in healthy male subjects
por: Roessler, Gernot, et al.
Publicado: (2018)

A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects
por: Hanes, Vladimir, et al.
Publicado: (2018)

An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects
por: Round, Patrick, et al.
Publicado: (2011)

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects
por: Hyland, Elizabeth, et al.
Publicado: (2016)

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
por: Lee, Sun Ku, et al.
Publicado: (2017)

The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers
por: Schneider, F., et al.
Publicado: (2021)

Safety, tolerability and pharmacokinetics of WXFL10203614 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase Ⅰ study
por: Huang, Kai, et al.
Publicado: (2022)

Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
por: Bendell, Johanna C., et al.
Publicado: (2018)

Pharmacokinetics and Tolerability of Single and Multiple Intravenous Doses of Cefotetan Disodium in Healthy Chinese Volunteers
por: Liu, Jian, et al.
Publicado: (2020)

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
por: Goadsby, Peter J, et al.
Publicado: (2019)

Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
por: DuBois, Janet, et al.
Publicado: (2021)

First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP‐ribose) Polymerase‐1 Inhibitor, JPI-289, in Healthy Volunteers
por: Han, Sungpil, et al.
Publicado: (2020)

Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects
por: Gillon, Jean‐Yves, et al.
Publicado: (2021)

Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers
por: Pawsey, Stephen, et al.
Publicado: (2016)

Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
por: Shi, Aixin, et al.
Publicado: (2020)

Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study
por: Zhao, Qian, et al.
Publicado: (2023)

2553. Safety, tolerability and pharmacokinetics of HS-10366 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase 1 trial
por: Liu, Xiaoyan, et al.
Publicado: (2023)

Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study
por: Pini, Luigi Alberto, et al.
Publicado: (2012)

Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study
por: Florian, Hana, et al.
Publicado: (2023)

Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia
por: Dowd, Sheila M, et al.
Publicado: (2020)

The effect of BI 409306 on heart rate in healthy volunteers: a randomised, double-blind, placebo-controlled, crossover study
por: Müller, Fabian, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants
por: Cheung, Tommy Tsang, et al.
Publicado: (2023)

A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects
por: Gu, Kenan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g2fta7veord8ju1p2keqf68pd3